If the official agrees to allow [redizumab] to enter the [clinical and social testing period] ahead of schedule, it gives cancer patients hope for life.
Then [Xuanhu Technology], or [Chaoqun Group] announced free measures, which made domestic cancer patients and their families excited.
They originally thought that after this [miraculous drug] was approved for marketing, the price would only be very high.
Like before, there was an injection called [Akilonsai].
This is an immunotherapy drug that belongs to CAR-T cell therapy and is mainly used to treat lymphoma.
There is a lymphoma patient in Lucheng. After being injected with this anti-cancer drug, after a 24-day drug action period, the cancer cells in the patient's body were eliminated.
This anti-cancer drug can eliminate cancer cells in the patient's body within a short period of time, mainly relying on the body's immune system.
Under normal circumstances, due to cell division in the human body, mutations will inevitably occur, and uncontrolled cells that can divide indefinitely—cancer cells—continue to appear.
Under normal circumstances, the body's immune tissues release immune cells to kill cancer cells that appear.
However, if the patient's own immunity is low, frail and sick, the immune system is inefficient, or for other reasons, then some cancer cells will become "fish that slip through the net" and mutate during constant division, making the body's immune cells unable to function normally.
If it is identified, it will naturally not be attacked.
These cancer cells continue to divide and form cancer tissue.
The principle of this anti-cancer drug is like a pair of "small scissors". It first cuts out fragments of the patient's immune system, then transforms them. After the transformation, it is injected back into the patient's body to achieve targeted elimination of cancer cells.
, the purpose of curing cancer.
In other words, through pioneering genetic medical technology, the immune system of cancer patients can be "strengthened" to have a certain ability to fight against a certain type of cancer. Then, with the help of the self-purification function of the immune system, the immune system of cancer patients can be thoroughly understood.
cancer cell.
Because of this, every medicine needs to be modified according to the patient's condition, that is, [private customization]. The cost of research and development has skyrocketed. The price of a CART anti-cancer drug can easily reach millions.
While the price is high, its efficacy is not effective against all cancers.
Because this kind of anti-cancer drug mostly targets blood tumors, not solid tumors. It also has a good effect on cancers where some cancer cells have spread into the blood, such as thyroid cancer, lymphoma, etc., and it also has a good effect on some melanomas.
Patients also have certain effects, which can inhibit the spread of some melanoma cancer cells. Through steady follow-up treatment, they can achieve cure. However, the effective rate only accounts for 50% of melanoma patients, and it is easy to develop very serious drug resistance.
sex.
On the battlefield against cancer, the main opponent has always been solid tumors, also known as tumors. However, the therapeutic effect of CART anti-cancer drugs on solid tumors is not as ideal as imagined, and the off-target rate is very high.
clinical value.
But even so, few people can afford the price of one million dollars.
After all, the incidence of poor diseases is high, the cure rate is difficult, and the prognosis is difficult to predict.
Although the clinical trial period of this [ledizumab] produced by [Xuanhu Technology] is short, its efficacy is amazing.
If it were not so prominent, [leditizumab] would not have been approved for emergency marketing and would have skipped the previous clinical stages.
Compared with CART anti-cancer drugs, [redizumab] is effective against almost all types of tumors, not just hematological tumors.
This means it has greater potential and clinical space.
For such a medicinal effect, if it sells for RMB 100,000, it is a conscientious price. If it sells for millions of yuan, even millions of yuan, those who are threatened with death will buy it even if they want to sell it.
But [Chaoqun Group] actually announced that [ledimumab] is free.
Although this is free, it is only in the social clinical testing stage.
Once the large-scale trial is successful, [leditizumab] will inevitably be charged.
And in order to recover previous losses, the fees must be high.
But even so, it is enough for these cancer patients and their families to be grateful.
For a time, the society was filled with words of praise for [Super Group] and Wu Siyuan.
Although Wu Siyuan didn't feel anything like this.
But this also means that his influence has been further improved.
Deep improvement!
Wu Siyuan laughed, if it was in ancient times, he might be someone like Wang Mang who had not usurped the throne.
Of course, it is impossible to usurp the throne in modern times.
Wu Siyuan doesn't like this either.
………………………………………………………………………………………………………………………………
Although Wu Siyuan announced that [leditimab] will be a free social clinical trial for cancer patients.
Theoretically, all cancer patients can get free [redizumab].
But in actual operation, this is not the case.
Only patients with advanced and terminal cancer are eligible for treatment with ledizumab.
Cancer patients in the early and middle stages can only receive traditional treatment first.
There is a problem with the production of [ledimumab].
After all, if it were fully rolled out, there would be 4.5 million copies in the country alone.
[Regeneration Cradle] Even the donkeys of the production team cannot produce so much in a short period of time.
Of course, Wu Siyuan is not worried about the final output.
Because the essence of [leditimab] is [nano-medical robot], after these [nano-medical robots] attack and kill the cancer cells in the patient's body, they will quietly leave the patient's body and eventually "return to the team".
The [Nano Medical Robot] produced by [Regeneration Cradle] is not a consumable, but will continue to accumulate.
Of course, it would be different if [nano medical robots] were used to treat injuries.
These [nano medical robots] cannot just return casually.
Except for the production issue.
In fact, another problem is security.
Wu Siyuan knows that his products have no safety issues.
After all, [ledimumab] is essentially a [nano-medical robot], not a drug. Taking [ledimumab] is equivalent to performing a nano-level surgical operation. How can there be any safety issues?
But others don’t know!
Although no obvious side effects have been found with [ledizumab] so far...well, to be precise, no side effects have been found.
But drugs are hard to say.
After all, the human body is very complex.
Some drugs often require more than ten years or decades of use before the side effects appear.
People above are also worried that if [leditizumab] has fatal side effects and breaks out at a later stage, it will be a disaster.
Whether it is for a company or a country.
so.
On the surface, [Chaoqun Group] will open [ledizumab] to all cancer patients.
But in fact, only patients with late-stage and terminal-stage cancer have the opportunity to get [redizumab].
Because, patients with advanced and terminal cancer are really hopeless.
[Ledizumab] No matter how bad the side effects are, it is not important to this type of patients.